Cover Image
市場調查報告書

全球勃起功能障礙(ED)治療藥市場

Global Erectile Dysfunction Drugs Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 312457
出版日期 內容資訊 英文 77 Pages
訂單完成後即時交付
價格
Back to Top
全球勃起功能障礙(ED)治療藥市場 Global Erectile Dysfunction Drugs Market 2014-2018
出版日期: 2014年09月10日 內容資訊: 英文 77 Pages
簡介

全球勃起功能障礙(ED)治療藥市場,預計從2013年到2018年之間,以4.47%的CAGR(年複合成長率)擴大。

本報告提供全球ED治療藥市場現狀分析與未來預測、各種類、用途、地區的趨勢、市場成長要素與課題、主要供應商的資訊等。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 各治療類型的市場區隔

第8章 主要藥物的市場評估

  • Viagra
    • 過去的銷售額
  • Cialis
    • 過去的銷售額
  • Levitra
    • 過去的銷售額

第9章 主要藥物的競爭評估

第10章 地理區隔

第11章 購買標準

第12章 罹患率和得病率

第13章 市場成長因素

第14章 成長因素與其影響

第15章 市場課題

第16章 成長因素與課題的影響

第17章 市場趨勢

第18章 趨勢與其影響

第19章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
  • 其他卓越供應商

第20章 主要供應商分析

  • Apricus Biosciences
  • Bayer AG
  • Dong-A Socio
  • Eli Lilly and Co.
  • Pfizer Inc.
  • Vivus

第21章 相關報告

目錄
Product Code: IRTNTR4092

About Erectile Dysfunction Drugs

A man's failure to sustain an erection that is adequate enough for sexual activity is known as erectile dysfunction. It also refers to the inconsistency to do so, or the inability to endure it for an extended period. Erectile dysfunction can be due to a number of reasons including aging, high blood pressure, diabetes mellitus, depression, smoking, nerve or spinal cord damage, alcoholism, and low testosterone levels. Treatments for erectile dysfunction include adopting a healthy lifestyle, oral phosphodiesterase type 5 (PDE5) inhibitors, vacuum devices, and surgery. Erectile dysfunction affects the quality of life and leads to stress, anxiety, and self-confidence problems. New research is undergoing in the field of erectile dysfunction to find more enhanced and effective therapies.

TechNavio's analysts forecast the Global Erectile Dysfunction Drugs market to decline at a CAGR of 4.47 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Erectile Dysfunction Drugs market for the period 2014-2018. The Global Erectile Dysfunction Drugs market can be divided into six segments: PDE 5 Inhibitors, Vacuum Constriction Device, Penile Prosthesis, Vascular Reconstructive Surgery, Injection Therapies, and Testosterone Replacement Therapy. To calculate the market size, the report considers the revenue generated from the sales of various drugs and topical creams used for the treatment of erectile dysfunction.

TechNavio's report, the Global Erectile Dysfunction Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Erectile Dysfunction Drugs market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Apricus Biosciences
  • Bayer
  • Dong-A Socio Holdings
  • Eli Lily
  • Pfizer
  • Vivus

Other Prominent Vendors

  • Auxillium Pharmaceuticals
  • Cristalia Produtos Quimicos Farmaceuticos
  • Futura Medical
  • Johnson & Johnson
  • Meda Pharmaceuticals
  • Pacific Therapeutics
  • Seattle Genetics

Market Driver

  • Increase in Aging Population

For a full, detailed list, view our report

Market Challenge

  • High Cost

For a full, detailed list, view our report

Market Trend

  • Increased Awareness of Erectile Dysfunction

For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Market Segmentation by Treatment

08. Market Assessment of Top Drugs

  • 08.1. Viagra
    • 08.1.1. Historic Sales
  • 08.2. Cialis
    • 08.2.1. Historic Sales
  • 08.3. Levitra
    • 08.3.1. Historic Sales

09. Competitive Assessment of Top Drugs

10. Geographical Segmentation

11. Buying Criteria

12. Rate of Incidence and Prevalence

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2013
  • 19.3. Other Prominent Vendors

20. Key Vendor Analysis

  • 20.1. Apricus Biosciences
    • 20.1.1. Key Facts
    • 20.1.2. Business Overview
    • 20.1.3. Geographical Segmentation by Revenue 2013
    • 20.1.4. Business Strategy
    • 20.1.5. Recent Developments
    • 20.1.6. SWOT Analysis
  • 20.2. Bayer AG
    • 20.2.1. Key Facts
    • 20.2.2. Business Overview
    • 20.2.3. Business Segmentation
    • 20.2.4. Business Strategy
    • 20.2.5. Sales Segmentation by Business
    • 20.2.6. Sales by Geographical Segmentation
    • 20.2.7. Key Information
    • 20.2.8. SWOT Analysis
  • 20.3. Dong-A Socio
    • 20.3.1. Key Facts
    • 20.3.2. Business Overview
    • 20.3.3. Business Segmentation
    • 20.3.4. Geographical Segmentation by Revenue 2013
    • 20.3.5. Business Strategy
    • 20.3.6. Recent Developments
    • 20.3.7. SWOT Analysis
  • 20.4. Eli Lilly and Co.
    • 20.4.1. Key Facts
    • 20.4.2. Business Overview
    • 20.4.3. Business Segmentation by Revenue 2013
    • 20.4.4. Business Segmentation by Revenue 2012 and 2013
    • 20.4.5. Sales by Geography
    • 20.4.6. Business Strategy
    • 20.4.7. Key Developments
    • 20.4.8. SWOT Analysis
  • 20.5. Pfizer Inc.
    • 20.5.1. Key Facts
    • 20.5.2. Business Description
    • 20.5.3. Business Segmentation
    • 20.5.4. Revenue by Business Segmentation
    • 20.5.5. Revenue Comparison 2012 and 2013
    • 20.5.6. Sales by Geography
    • 20.5.7. Business Strategy
    • 20.5.8. Key Developments
    • 20.5.9. SWOT Analysis
  • 20.6. Vivus
    • 20.6.1. Key Facts
    • 20.6.2. Business Overview
    • 20.6.3. Business Segmentation by Revenue 2013
    • 20.6.4. Business Segmentation by Revenue 2012 and 2013
    • 20.6.5. Geographical Segmentation by Revenue 2013
    • 20.6.6. Business Strategy
    • 20.6.7. Recent Developments
    • 20.6.8. SWOT Analysis

21. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Erectile Dysfunction Drugs Market 2013-2018 (US$ billion)
  • Exhibit 3: Global Erectile Dysfunction Drugs Market Segmentation by Treatment
  • Exhibit 4: Pfizer's Viagra Revenue 2010-2013 (US$ million)
  • Exhibit 5: Eli Lily's Cialis Revenue 2010-2013 (US$ million)
  • Exhibit 6: Bayer's Levitra Revenue 2010-2013 (US$ million)
  • Exhibit 7: Sales of Top 3 Erectile Dysfunction Drugs FY 2010-2013 (US$ million)
  • Exhibit 8: Sales of Top 3 Erectile Dysfunction Drugs FY 20010-2013 (US$ million)
  • Exhibit 9: Global Erectile Dysfunction Drugs Market by Geographical Segmentation 2013
  • Exhibit 11: Apricus Biosciences: Geographical Segmentation by Revenue 2013
  • Exhibit 12: Business Segmentation of Bayer AG 2013
  • Exhibit 13: Sales Comparison of Bayer AG by Business Segment 2012 and 2013 (US$ million)
  • Exhibit 14: Sales Segmentation of Bayer AG by Geography 2013
  • Exhibit 15: Dong-A Socio: Business Segmentation 2013
  • Exhibit 16: Dong-A Socio: Geographical Segmentation by Revenue 2013
  • Exhibit 17: Eli Lilly and Co.: Business Segmentation by Revenue 2013
  • Exhibit 18: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 19: Eli Lilly and Co.: Sales by Geography 2013
  • Exhibit 20: Pfizer Inc.: Business Segmentation
  • Exhibit 21: Pfizer Inc.: Revenue by Business Segmentation 2013
  • Exhibit 22: Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
  • Exhibit 23: Pfizer Inc.: Revenue by Geography 2013
  • Exhibit 24: Global Erectile Dysfunction Drugs Market: Business Segmentation by Revenue 2013
  • Exhibit 25: Global Erectile Dysfunction Drugs Market: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 26: Global Erectile Dysfunction Drugs Market: Geographical Segmentation by Revenue 2013
Back to Top